Cholinesterase inhibitors for the treatment of Alzheimer's disease:: getting on and staying on.

ChE inhibitors provide symptomatic benefit in AD across key symptom domains using slow, flexible dose escalation and factors influencing the safety, tolerability, and efficacy of these agents in clinical practice include ChE enzymes inhibited, brain and brain-region ChE selectivity, and metabolism route.